What is the purpose of this study?Percutaneous intercostal biliary drain placement for benign biliary strictures is a relatively common procedure in interventional radiology that often results in increased morbidity in the acute and subacute postprocedural period, with pain often being the most common adverse outcome experienced by patients. Our purpose with this study is to prospectively compare pain relief in the acute and subacute periprocedural period, as measured by visual analog scale, between preprocedural intercostal nerve block with bupivicaine + methylprednisolone vs standard of care (general anesthesia and local/subcutaneous lidocaine injection) in patients with benign biliary strictures whom present for first-time biliary catheter placement. The intervention arm will receive both standard of care plus the intervention nerve block with bupivacaine and methylprednisolone. THIS STUDY IS ENROLLING BY INVITATION ONLY - Research will take place at IU Health hospitals (University and Methodist Hospitals) in Indianapolis, Indiana. Patients will be identified t he day-of, or day-prior, to their catheter placement given the usual nature of this disease process at presentation. Eligible subjects who present for initial right-sided percutaneous biliary catheter placement will be evaluated for inclusion in this study. 

What is the purpose of this study?Food insecurity is a prevalent social determinant of health among safety-net primary care patients. Among adults with food insecurity, conditions like hypertension (HTN) and type 2 diabetes (DM2) are as much as two times more prevalent. This project will evaluate FoRKS (home delivered foods and kitchen skills intervention) versus enhanced usual care (EUC) for middle-aged safety-net primary care patients who screen positive for food insecurity and hypertension. This is a randomized clinical trial (RCT) testing the feasibility and initial efficacy of FoRKS to impact mean systolic blood pressure immediately post-intervention.

What is the purpose of this study?The purpose of this research study is to determine if the Enterra® Therapy System can decrease nausea and vomiting symptoms and improve the quality of life for patients with chronic nausea, with or without vomiting, that have normal gastric emptying. THIS STUDY IS ENROLLING BY INVITATION ONLY

What is the purpose of this study?The purpose of this study is to better understand how parents of infants and young children (3 years of age and under) experience the stem cell transplant process. More specifically, we want to understand if and how stem cell transplant impacts parenting so that supportive interventions can be tailored to the unique needs of parents of infants and young children undergoing stem cell transplantation. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

What is the purpose of this study?Primary To compare antitumor activity in ORR per Response Evaluation Criteria in Solid Tumor (RECIST) Guidelines version (v) 1.1 as assessed by blinded independent central review (BICR) in patients with incurable metastatic / recurrent HNSCC patients progressed on after anti-PD-1 and platinum containing therapy, treated with petosemtamab monotherapy vs investigator s choice monotherapy To compare OS in patients with incurable metastatic / recurrent HNSCC progressed on after anti-PD-1 and platinum-containing therapy, treated with petosemtamab monotherapy vs investigator s choice monotherapy Secondary To evaluate antitumor activity in ORR per RECIST v1.1 as assessed by investigator review To evaluate antitumor activity in DOR per RECIST v1.1 as assessed by BICR and investigator review To evaluate antitumor activity in TTR per RECIST v1.1 as assessed by BICR and investigator review To evaluate antitumor activity in PFS per RECIST v1.1 as assessed by BICR and by investigator review To evaluate antitumor activity in CBR per RECIST v1.1 as assessed by BICR and by investigator review Exploratory To explore the relevant tumor biomarkers in tumor and blood samples predictive of response or resistance to therapy THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

What is the purpose of this study?The purpose of this study is to determine if an outpatient population of pediatric patients with nausea related to a disorder of gut-brain interaction (DGBI) have decreased symptoms after use of aromatherapy (QueaseEase) as measured by the Nausea ProfileTHIS STUDY IS ENROLLING BY INVITATION ONLY - Pediatric patients ages 9-18 seen in an ambulatory subspecialty DGBI pediatric gastroenterology clinic at a quaternary care center will be identified and approached by the study team about study participation.  On their first visit to the DGBI clinic, treatment will be based on shared decision making between investigator, patient, and caregivers. Based on patient preference, they may receive QueaseEase aromatherapy.